HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010
(ots/PRNewswire) -- Agendia, a world leader in molecular cancer
diagnostics, today announced that its breast cancer product offering,
consisting of breast cancer recurrence test MammaPrint(R), and
TargetPrint(TM), has been expanded with BluePrint (TM) to report
important additional information on tumor subtypes. This new service
is based on an 80-gene signature that identifies the basal-like,
luminal-like, and HER2 molecular subtypes in breast cancer tumors.

"Using BluePrint, we will research potentially different
responses of therapies to biologically different subgroups together
with our customers. In the future, we envision the clinical utility
of a combination of BluePrint with MammaPrint's original 70-gene
panel," said Richard Bender, MD, FACP, Chief Medical Officer of
Agendia. "We believe this combination has great potential to bring
the personalized treatment of breast cancer patients to a new level."

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA
clearance under the in vitro diagnostic multivariate index assay
(IVDMIA) guidelines requires clinical and analytical validation and
reporting systems to ensure patient safety issues are addressed.
Highly accurate, MammaPrint identifies patients with early
metastasis-patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test results provide doctors with
a clear rationale to assess the benefit of chemotherapy in addition
to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited
service laboratory. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous
FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting-edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. The Company was awarded the 2008 North American
Oncology Clinical Diagnostics Healthcare Innovation Award by Frost &
Sullivan. Agendia is based in Huntington Beach, California, and in
Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: MEDIA CONTACTS: Hans Herklots, Head of Corporate
Communications,Agendia, +31-20-462-1557 Office, +31-620-083-509
Mobile, Diese E-Mail-Adresse ist gegen Spam Bots geschützt, Sie müssen JavaScript aktivieren, damit Sie es sehen können ; Valerie Delva, Account Executive,
RicochetPublic Relations, +1-212-679-3300 x131 Office,
Diese E-Mail-Adresse ist gegen Spam Bots geschützt, Sie müssen JavaScript aktivieren, damit Sie es sehen können